NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Forecast & News

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Five Prime Therapeutics Inc (NASDAQ:FPRX) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.95) by $0.08. The biotechnology company earned $2.98 million during the quarter, compared to analysts' expectations of $4.33 million. Five Prime Therapeutics had a negative net margin of 921.30% and a negative return on equity of 65.39%. View Five Prime Therapeutics' Earnings History.

Five Prime Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Five Prime Therapeutics.

Five Prime Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

5 equities research analysts have issued 12 month price targets for Five Prime Therapeutics' stock. Their forecasts range from $5.00 to $24.00. On average, they anticipate Five Prime Therapeutics' share price to reach $12.25 in the next twelve months. This suggests a possible upside of 134.2% from the stock's current price. View Analyst Price Targets for Five Prime Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Five Prime Therapeutics.

Media headlines about FPRX stock have trended negative this week, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Five Prime Therapeutics earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Five Prime Therapeutics.

Five Prime Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,710,000 shares, an increase of 14.0% from the January 15th total of 1,500,000 shares. Based on an average daily volume of 488,500 shares, the days-to-cover ratio is currently 3.5 days. Approximately 4.8% of the shares of the stock are sold short. View Five Prime Therapeutics' Current Options Chain.

Some companies that are related to Five Prime Therapeutics include Basilea Pharmaceutica (BPMUF), Kadmon (KDMN), Urogen Pharma (URGN), Flexion Therapeutics (FLXN), Phoenix Tree (IMAB), ZIOPHARM Oncology (ZIOP), Atreca (BCEL), XBiotech (XBIT), Clovis Oncology (CLVS), AC Immune (ACIU), Assembly Biosciences (ASMB), Ardelyx (ARDX), Molecular Templates (MTEM), Kura Oncology (KURA) and Crinetics Pharmaceuticals (CRNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Novavax (NVAX), Opko Health (OPK), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), TherapeuticsMD (TXMD) and Clovis Oncology (CLVS).

Five Prime Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (21.39%), Renaissance Technologies LLC (4.84%), State Street Corp (1.72%), Man Group plc (1.50%), AQR Capital Management LLC (1.23%) and Jacobs Levy Equity Management Inc. (0.99%). Company insiders that own Five Prime Therapeutics stock include Andrew T Feldstein, Bvf Partners L P/Il, Franklin M Berger and Value Fund L P Biotechnology. View Institutional Ownership Trends for Five Prime Therapeutics.

FPRX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Assenagon Asset Management S.A., AXA, UBS Group AG, State Street Corp, Citigroup Inc., Bank of New York Mellon Corp and Algert Global LLC. View Insider Buying and Selling for Five Prime Therapeutics.

FPRX stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Renaissance Technologies LLC, AQR Capital Management LLC, Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, Russell Investments Group Ltd., Platinum Investment Management Ltd. and Fred Alger Management LLC. Company insiders that have bought Five Prime Therapeutics stock in the last two years include Andrew T Feldstein, Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Five Prime Therapeutics.

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FPRX stock can currently be purchased for approximately $5.23.

Five Prime Therapeutics has a market capitalization of $190.33 million and generates $49.87 million in revenue each year. The biotechnology company earns $-140,450,000.00 in net income (profit) each year or ($4.13) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe.View Additional Information About Five Prime Therapeutics.

The official website for Five Prime Therapeutics is http://www.fiveprime.com/.

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]